Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical Transplantation

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Melhem Solh, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138572

Published: 2020

Journal Articles

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Alexander M. Lesokhin, MD, Moshe Y. Levy, MD, Andrew P. Dalovisio, MD, Nizar J. Bahlis, MD, Melhem Solh, MD, Michael Sebag, MD PhD FRCPC, Andrzej Jakubowiak, MD PhD, Yogesh S. Jethava, MBBS, MD FRCPath, MRCP, Caitlin L. Costello, MD, Michael P. Chu, MD, Michael R. Savona, MD, Cristina Gasparetto, MD, Suzanne Trudel, MD MSC, FRCPC, Jeffrey Chou, MD PhD, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Heike I. Krupka, PhD PMP, Noopur S. Raje, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133355

Published: 2020

Journal Articles

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paolo F Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, MD, Kirit M. Ardeshna, Mehdi Hamadani, MD, Brian T. Hess, MD, Brad S. Kahl, MD, John A. Radford, MD FMedSci, Melhem Solh, MD, Anastasios Stathis, MD, Pier Luigi Zinzani, MD, Jay Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo-Stella, MD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-137524

Published: 2020

Journal Articles

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Alice S. Mims, MD, Melhem Solh, MD, Uma Borate, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Gail J. Roboz, MD, Ben Powell, PhD, Paul Severson, PhD, Bernice Matusow, Jason Halladay, PhD, Ching Hsu, PhD, Paul Watkins, Chao Zhang, PhD, Jackie M. Walling, PhD MD, Athanasios C. Tsiatis, MD, Amy E. DeZern, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-140138

Published: 2020

Journal Articles

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem Solh, MD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 2006.

https://doi.org/10.1182/blood-2019-123230

Published: 2019

Journal Articles

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Melhem Solh, MD

Blood (2019) 134 (Supplement_1): 2014.

https://doi.org/10.1182/blood-2019-125229

Published: 2019

Journal Articles

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, MD, Melhem Solh, MD, Stacey Brown, CCRP, Katelin C Jackson, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 1998.

https://doi.org/10.1182/blood-2019-124354

Published: 2019

Journal Articles

Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Morbidity Score

Melhem Solh, MD, Dawn Speckhart, PhD, Xu Zhang, PhD, Asad Bashey, MD PhD, Scott R. Solomon, MD, Lawrence E Morris, MD, H. Kent Holland, MD

Blood (2019) 134 (Supplement_1): 3493.

https://doi.org/10.1182/blood-2019-131639

Published: 2019

Journal Articles

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Naveen Pemmaraju, MD, Uma Borate, MD, Melhem Solh, MD, Gautam M. Borthakur, MD, Amy E. DeZern, MD, Chao Zhang, PhD, Ben Powell, PhD, Paul Severson, Kerry Inokuchi, Bernice Matusow, Jason Halladay, Ching Hsu, PhD, Paul Watkins, Jackie M. Walling, PhD MD, Athanasios C. Tsiatis, MD, Alice S. Mims, MD

Blood (2019) 134 (Supplement_1): 1391.

https://doi.org/10.1182/blood-2019-127497

Published: 2019

Journal Articles

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Carmelo Carlo-Stella, MD, Pier Luigi Luigi Zinzani, MD, Brad S. Kahl, MD, Paolo F Caimi, MD, Melhem Solh, MD, William Townsend, MRCP,MDFRCPath, Anastasios Stathis, MD, Elizabeth H. Cull, MD, Mehdi Hamadani, MD, Alexander I. Spira, PhD MD FACP, Jay Feingold, MD PhD, David Ungar, MD, Shui He, PhD, Yajuan Qin, John Radford

Blood (2019) 134 (Supplement_1): 757.

https://doi.org/10.1182/blood-2019-128401

Published: 2019

Journal Articles

Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy

Melhem Solh, MD, Xu Zhang, PhD, Asad Bashey, MD PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 4541.

https://doi.org/10.1182/blood-2019-131661

Published: 2019

Journal Articles

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

Melhem Solh, MD, Scott R. Solomon, MD, H. Kent Holland, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 4479.

https://doi.org/10.1182/blood-2019-131624

Published: 2019

Journal Articles

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

Eva Karam, PharmD, Justin LaPorte, PharmD, Connie Sizemore, PharmD, Xu Zhang, PhD, H. Kent Holland, MD, Melhem Solh, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 3269.

https://doi.org/10.1182/blood-2019-131365

Published: 2019

Journal Articles

A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies

Melhem Solh, MD, Scott R. Solomon, MD, Xu Zhang, PhD, H. Kent Holland, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 3333.

https://doi.org/10.1182/blood-2019-131608

Published: 2019

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

https://doi.org/10.1182/blood-2019-125865

Published: 2019

Journal Articles

Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

John Radford, MD FRCP, Brad S. Kahl, MD, Mehdi Hamadani, MD, Carmelo Carlo-Stella, MD, Paolo Caimi, MD, Kirit M. Ardeshna, MBBChir, Jay Feingold, MD PhD, Shui He, PhD, Erin Reid, MD, Melhem Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, David Ungar, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 398.

https://doi.org/10.1182/blood-2018-99-116081

Published: 2018

Journal Articles

Treatment Patterns and Outcomes of Unselected Elderly Acute Myeloid Leukemia (AML) Patients Referred to a Combined Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program

Scott R Solomon, MD, Katelin C Jackson, Xu Zhang, PhD, Melhem Solh, MD, Asad Bashey, MD PhD, H. Kent Holland, MD, Lawrence E Morris, MD

Blood (2018) 132 (Supplement 1): 2675.

https://doi.org/10.1182/blood-2018-99-111048

Published: 2018

Journal Articles

The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease

Melhem Solh, MD, Scott R Solomon, MD, Lawrence E Morris, MD, H. Kent Holland, MD, Xu Zhang, PhD, Asad Bashey, MD PhD

Blood (2018) 132 (Supplement 1): 82.

https://doi.org/10.1182/blood-2018-99-118789

Published: 2018

Journal Articles

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

Blood (2018) 132 (Supplement 1): 1407.

https://doi.org/10.1182/blood-2018-99-117231

Published: 2018

Journal Articles

Transplant Rates and Outcomes of Young Acute Myeloid Leukemia (AML) Patients with Intermediate and Poor Risk Disease Referred to a Coordinated Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program

Melhem Solh, MD, Xu Zhang, PhD, Asad Bashey, MD PhD, Lawrence E Morris, MD, Zain Bashey, H. Kent Holland, MD, Scott R Solomon, MD

Blood (2018) 132 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2018-99-119185

Published: 2018

NARROW

CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical Transplantation

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Morbidity Score

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Treatment Patterns and Outcomes of Unselected Elderly Acute Myeloid Leukemia (AML) Patients Referred to a Combined Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program

The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

Transplant Rates and Outcomes of Young Acute Myeloid Leukemia (AML) Patients with Intermediate and Poor Risk Disease Referred to a Coordinated Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only